Alejandra Cabral, Jared M Baeten1,2, Kenneth Ngure3, Jennifer Velloza1, Josephine Odoyo4, Jessica E Haberer5, Connie Celum1,2, Timothy Muwonge6, Stephen Asiimwe7, Renee Heffron1. 1. Epidemiology. 2. Medicine, University of Washington, Seattle, WA. 3. Department of Public Health, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Juja, Kenya. 4. Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya. 5. Department of Global Health, Harvard Medical School, Massachusetts General Hospital, Boston, MA. 6. Infectious Disease Institute, Makerere University, Kampala, Uganda. 7. Kabwohe Clinical Research Center, Kabwohe, Uganda.
Abstract
BACKGROUND: Oral pre-exposure prophylaxis (PrEP) is effective for HIV prevention, and PrEP delivery studies are investigating ways to deliver PrEP with high adherence. However, in many settings with high HIV burden, intimate partner violence (IPV) is reported often and could be a barrier to the effective PrEP use. We examined the association between IPV and interruptions in PrEP use. METHODS: We analyzed data from 1013 serodiscordant heterosexual couples enrolled in a large PrEP demonstration project in Kenya and Uganda, the Partners Demonstration Project. At quarterly study visits, HIV-negative participants receiving PrEP were asked about interruptions in their PrEP use and experiences with IPV. The association between IPV and PrEP interruptions was analyzed using multivariable generalized estimating equations. RESULTS: At baseline and follow-up, there were 53 visits with reports of abuse by 49 HIV-negative partners, including physical, economic, and verbal IPV. Interruptions in PrEP use were reported at 328 visits (7.1% of all visits) by 249 people. The median length of PrEP interruption was 28 days (interquartile range: 7-45). The frequency of PrEP interruptions among those reporting IPV was 23.8% and those without IPV was 6.9%. PrEP interruption was significantly associated with IPV after adjustment for age and frequency of sexual intercourse (adjusted odds ratio = 2.6, 95% confidence interval: 1.2 to 6.0). CONCLUSIONS: IPV was more likely to be reported at visits when PrEP interruptions were also reported, which may have implications for sustained adherence to PrEP. Within PrEP delivery programs, there may be opportunities to assess individual safety and well-being to bolster adherence.
BACKGROUND: Oral pre-exposure prophylaxis (PrEP) is effective for HIV prevention, and PrEP delivery studies are investigating ways to deliver PrEP with high adherence. However, in many settings with high HIV burden, intimate partner violence (IPV) is reported often and could be a barrier to the effective PrEP use. We examined the association between IPV and interruptions in PrEP use. METHODS: We analyzed data from 1013 serodiscordant heterosexual couples enrolled in a large PrEP demonstration project in Kenya and Uganda, the Partners Demonstration Project. At quarterly study visits, HIV-negative participants receiving PrEP were asked about interruptions in their PrEP use and experiences with IPV. The association between IPV and PrEP interruptions was analyzed using multivariable generalized estimating equations. RESULTS: At baseline and follow-up, there were 53 visits with reports of abuse by 49 HIV-negative partners, including physical, economic, and verbal IPV. Interruptions in PrEP use were reported at 328 visits (7.1% of all visits) by 249 people. The median length of PrEP interruption was 28 days (interquartile range: 7-45). The frequency of PrEP interruptions among those reporting IPV was 23.8% and those without IPV was 6.9%. PrEP interruption was significantly associated with IPV after adjustment for age and frequency of sexual intercourse (adjusted odds ratio = 2.6, 95% confidence interval: 1.2 to 6.0). CONCLUSIONS: IPV was more likely to be reported at visits when PrEP interruptions were also reported, which may have implications for sustained adherence to PrEP. Within PrEP delivery programs, there may be opportunities to assess individual safety and well-being to bolster adherence.
Authors: Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba Journal: J Infect Dis Date: 2016-02-24 Impact factor: 5.226
Authors: Edwin Were; Kathryn Curran; Sinead Delany-Moretlwe; Edith Nakku-Joloba; Nelly R Mugo; James Kiarie; Elizabeth A Bukusi; Connie Celum; Jared M Baeten Journal: AIDS Date: 2011-10-23 Impact factor: 4.177
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Miriam Hartmann; Michele Lanham; Thesla Palanee-Phillips; Florence Mathebula; Elizabeth E Tolley; Dean Peacock; Laura Pascoe; Seth Zissette; Sarah T Roberts; Danielle Wagner; Ellen Wilson; Asha Ayub; Rose Wilcher; Elizabeth T Montgomery Journal: AIDS Educ Prev Date: 2019-10
Authors: Jennifer Velloza; Deborah Donnell; Sybil Hosek; Peter L Anderson; Z Mike Chirenje; Nyaradzo Mgodi; Linda-Gail Bekker; Mark A Marzinke; Sinead Delany-Moretlwe; Connie Celum Journal: Lancet HIV Date: 2022-09-07 Impact factor: 16.070
Authors: Jillian Pintye; Kristin M Beima-Sofie; Pamela A Makabong'O; Anne Njoroge; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Connie Celum; Daniel Matemo; John Kinuthia; Maureen C Kelley; Grace C John-Stewart Journal: AIDS Patient Care STDS Date: 2018-07-23 Impact factor: 5.078
Authors: Fernandos K Ongolly; Annabel Dolla; Kenneth Ngure; Elizabeth M Irungu; Josephine Odoyo; Elizabeth Wamoni; Kathryn Peebles; Kenneth Mugwanya; Nelly R Mugo; Elizabeth A Bukusi; Jennifer Morton; Jared M Baeten; Gabrielle O'Malley Journal: J Acquir Immune Defic Syndr Date: 2021-05-01 Impact factor: 3.771
Authors: Alexandra M Minnis; Emily Krogstad; Mary Kate Shapley-Quinn; Kawango Agot; Khatija Ahmed; L Danielle Wagner; Ariane van der Straten Journal: Sex Reprod Health Matters Date: 2021-12